Doylestown, PA, United States of America

Russell Gotschall

This inventor holds 17 USPTO granted patents and 14 published patent applications, plus 1 CIPO patent and 9 EPO patents, primarily in Recombinant Enzyme Therapy. Top assignee: Amicus Therapeutics, Inc.. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Russell Gotschall. Retrieved from https://idiyas.com/inventor/russell-gotschall

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 17 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 2.6

ph-index = 5

Forward Citations = 53(Granted Patents)


Location History:

  • Cranbury, NJ (US) (2020 - 2022)
  • Doylestown, PA (US) (2019 - 2023)

Company Filing History:


Years Active: 2019-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Acid Alpha-Glucosidase
Recombinant Proteins
Pompe Disease
Fabry Disease
Gene Therapy
M6P Selection
Therapeutic Formulations
Potent Enzymes
17 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Russell Gotschall

Introduction

Russell Gotschall, a prominent inventor based in Doylestown, PA, has made significant contributions to the field of biopharmaceuticals. With a portfolio of 14 patents, he has demonstrated a commitment to advancing medical science, particularly in relation to treating rare diseases.

Latest Patents

Among his recent innovations are two notable patents focusing on recombinant human acid alpha-glucosidase. The first patent details a recombinant acid α-glucosidase and a pharmaceutical composition that showcases this enzyme, expressed in Chinese hamster ovary (CHO) cells. This composition boasts an increased content of N-glycan units that bear one or two mannose-6-phosphate residues, enhancing its therapeutic potential over existing treatments like alglucosidase alfa. The second patent describes a highly potent recombinant human alpha glucosidase (rhGAA) derived from CHO cells. This innovative formulation features an optimized glycan composition with a higher density of N-glycans containing mannose-6-phosphate (M6P) or bis-M6P, thereby improving efficacy and reducing the presence of non-phosphorylated high mannose glycans.

Career Highlights

Russell has dedicated his career to biopharmaceutical innovation and currently serves at Amicus Therapeutics, Inc., where he leverages his expertise to develop treatments for conditions such as Pompe disease. His work exemplifies how targeted research can lead to groundbreaking advancements in patient care.

Collaborations

Throughout his career, Russell has collaborated with talented professionals in the field, including Hung V Do and Hing Char. These partnerships underscore the collaborative nature of scientific research and the importance of teamwork in fostering innovation.

Conclusion

Russell Gotschall's contributions to the field of biopharmaceuticals through his innovative patents reflect his dedication to improving healthcare outcomes. His work not only represents significant advancements in the treatment of rare diseases but also highlights the importance of collaboration and continuous research in driving innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…